THE ROLE OF ETHYL ACETATE FRACTION OF ANDROGRAPHIS PANICULATA AND DOXORUBICIN COMBINATION TOWARD THE INCREASE OF APOPTOSIS AND DECREASE OF VEGF PROTEIN EXPRESSION OF MICE FIBROSARCOMA CELLS
Keywords:
Andrographis paniculata, Doxorubicin, Apoptosis, VEGF, Fibrosarcoma, Benzo(a)pyreneAbstract
Objective: The objective of this study is to prove the role of an ethyl acetate fraction of Andrographis paniculata and doxorubicin combination toward the increase of apoptosis and decrease of VEGF protein expression of mice fibrosarcoma cells.
Methods: The mice were injected subcutaneously on the scapular with benzo(a)pyrene once every 2 days for 10 days to induce fibrosarcoma and after 3 months they were randomly divided into four groups, consisting of: negative control, ethyl acetate fraction of A. paniculata group, doxorubicin group, and combination of ethyl acetate fraction of A. paniculata and doxorubicin group. By immunohistochemistry preparation, fibrosarcoma cells were scored for apoptosis and VEGF protein expression.
Results: Ethyl acetate fraction of A. paniculata and doxorubicin combination significantly (p<0.05) increase apoptosis. Ethyl acetate fraction of A. paniculata and doxorubicin combination also significantly (p<0.05) decrease VEGF protein expression.
Conclusion: It can be concluded that ethyl acetate fraction of A. paniculata and doxorubicin combination increase apoptosis and decrease VEGF protein expression of mice fibrosarcoma cells. Decrease of VEGF protein expression led to an inhibition of tumor growth, tumor neovascularization, decrease in proliferation of tumor cells and the formation of necrosis.
Â
Downloads
References
Arnoult D. Apoptosis-associated mitochondrial outer membrane permeabilization assays. Methods 2008;44:229-34.
Iruretagoyena MI, Tobar JA, Gonzalez PA, Sepulveda SE, Figueroa CA, Burgos RA, et al. Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. J Pharmacol Exp Ther 2005;312:366-72.
Poolsup N, Suthisisang C, Prathanturarug S, Asawamekin A, Chanchareon U. A. A. paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials. J Clin Pharm Ther 2004;29:37-45.
Chang J, Zhang RM, Zhang Y, Chen ZB, Zhang ZM, Xu Q, et al. Andrographolide drop-pill in treatment of acute upper respiratory tract infection with external wind-heat syndrome: a multicenter and randomized controlled trial. Zhongxiyi Jiehe Xuebao 2008;6:1238-45.
Calabrese C, Berman SH, Babish JG, Ma X, Shinto L, Dorr M, et al. A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytother Res 2000;14:333-8.
Nanduri S, Nyavanandi VK, Thunuguntla SS, Kasu S, Pallerla MK, Ram PS, et al. Synthesis and structure-activity relationships of andrographolide analogues as novel cytotoxic agents. Bioorg Med Chem Lett 2004;14:4711-7.
Varma A, Padh H, Shrivastava N. Andrographolide: a new plant-derived antineoplastic entity on horizon. Evidence-Based Complementary Altern Med 2011;8(1)1-9.
Zhou J, Ong CN, Hur GM, Shen HM. Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin. Biochem Pharmacol 2010;79:1242-50.
Sukardiman, Santosa MH, Rahman A, Studiawan H. Ethyl acetat fraction of Andrographis paniculata Nees Increase Cytotoxic Effect of 5-Flourouracil on Human cancer Cell Lines. Int J Pharm Pharm Sci 2014;6(5):67-71.
Nowak M, Madej JA, Dziegiel P. Intensity of COX-2 Expression in cells of soft tissue fibrosarcomas in dogs as related to grade of tumour malignancy. Bull Vet Inst Pulawy 2007;51:275-9.
Thorburn A. Death receptor-induced cell killing. Cell Signal 2004;16(2):139-44.
Ozoren N, El-Deiry WS. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 2003;13(2):135-47.
Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003;10(1):26-35.
Lehnhardt M, Klein-Hitpass L, Kuhnen C, Homann HH, Daigeler A, Steinau HU, et al. Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer 2005;5:74.
Kim TG, Hwi KK, Hung CS. Morphological and biochemical changes of andrographolide-induced cell death in human prostatic adenocarcinoma PC-3 cells. In vivo 2005;19(3):551-8.
Zhou J, Zhang S, Ong CN, Shen HM. Critical role of pro-apoptotic Bcl-2 family members in andrographolide-induced apoptosis in human cancer cells. Biochem Pharmacol 2006;72(2):132-44.
Zhou J, Lu GD, Ong CS, Ong CN, Shen HM. Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation. Mol Cancer Ther 2008;7(7):2170-80.
Han Y, Bu LM, Ji X, Liu CY, Wang, ZH. Modulation of multidrug resistance by andrographolide in a HCT-8/5-FU multidrug-resistant colorectal cancer cell line. Chin J Dig Dis 2005;6(2):82-6.
Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
Cherrington JM, Strawn LM, Shawver LK. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res 2000;79:1-38.
Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci 2005;109:227-41.
Kim YJ, Lee HJ, Kim TM, Eisinger-Mathason K, Zhang AY, Schmidt B, et al. Overcoming evasive resistance from vascular endothelial growth factor A inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α. Int J Cancer 2013;132:29.
Sheeja K, Guruvayoorappan C, Kuttan G. Antiangiogenic activity of A. paniculata extract and andrographolide. Int Immunopharmacol 2007;(7):211-21.
Prewett M, Huber J, Li Y, Santiago A, O’Connor W, King K, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59:5209-18.